Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers

NCT00291473 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Cancer
Lung Cancer
Stomach Cancer
Breast Cancer
Ovarian Cancer

Interventions

DRUG: CHP-HER2, CHP-NY-ESO-1

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]